Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis
- 15 May 2008
- journal article
- Published by Wiley in European Journal of Neurology
- Vol. 15 (7), 677-680
- https://doi.org/10.1111/j.1468-1331.2008.02146.x
Abstract
A short course of intravenous methylprednisolone (IVMP) followed by oral prednisone taper (OPT) is often used for the treatment of relapses in multiple sclerosis (MS). We examined the effect of IVMP plus OPT compared with IVMP only on neurologic disability 1 year after treatment of a relapse in patients with relapsing-remitting multiple sclerosis. Two hundred eighty-five consecutive relapses were analyzed in a retrospective fashion. One hundred fifty-two patients with a total of 171 relapses received IVMP plus an OPT at the time of relapse whilst 112 patients who experienced 114 relapses received IVMP without OPT. There was no difference between the two groups in the baseline characteristics as well as the mean or categorical EDSS at baseline, at the time of relapse confirmation, and at months 3, 6 and 12 after relapse confirmation. Our observations suggest that OPT following treatment with IVMP for an MS relapse does not lead to improved neurologic outcome after 12 months compared with treatment with IVMP only. Moreover, our findings raise concerns regarding the common practice of using OPT following IVMP. Further studies are indicated to validate our findings and minimize exposure to systemic corticosteroids, well known for systemic toxicity.Keywords
This publication has 20 references indexed in Scilit:
- EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapsesEuropean Journal of Neurology, 2005
- Steriods for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trialsZeitschrift für Neurologie, 2000
- Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohortsJournal of Neurology, Neurosurgery & Psychiatry, 2000
- Recovery of the hypothalamic-pituitary-adrenal axis from suppression by short-term, high-dose intravenous prednisolone therapy in patients with MSActa Neurologica Scandinavica, 1994
- Hypothalamic-pituitary-adrenal function one week after a short burst of steroid therapyJournal of Clinical Endocrinology & Metabolism, 1993
- A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic NeuritisNew England Journal of Medicine, 1992
- High‐dose intravenous methylprednisolone in the treatment of multiple sclerosisNeurology, 1986
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- Complications of Corticosteroid TherapyArchives of Pediatrics & Adolescent Medicine, 1978
- RECOVERY OF HYPOTHALAMO-PITUITARY-ADRENAL FUNCTION AFTER CORTICOSTEROID THERAPYThe Lancet, 1967